nach oben

Irish Journal of Medical Science (1971 -)

Erschienen in:

01.06.2014 | Original Article

Elevated prevalence of abnormal glucose metabolism in patients with primary aldosteronism: a meta-analysis

verfasst von: W. Chen, F. Li, C. He, Y. Zhu, W. Tan

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Objective

To conduct a meta-analysis of studies assessing abnormal glucose metabolism (AGM) prevalence among patients with primary aldosteronism (PA), calculating a combined pooled prevalence and summarizing metabolic parameters associated the pooled prevalence for comparative group.

Method

Four electronic databases (PubMed, EMBASE, Cochrane CENTRAL, and ISI-Web of Science) were systematically retrieved with no language and time restriction. Studies about elevated level of glucose metabolism in primary aldosteronism were included.

Result

Data were available in 16 studies. The pooled analysis revealed that the prevalence of elevated glucose in PA was 22.41 % (95 % CI 16.77–28.05 %), the retrospectively calculated prevalence was 31.20 % (95 % CI 15.81–46.60 %) for impaired fasting glucose, 26.19 % (95 % CI 15.17–37.21 %) for impaired glucose tolerance, 15.22 % (95 % CI 9.93–20.51 %) for diabetes mellitus. Prevalence of AGM in PA was higher than that in essential hypertension (OR = 1.55, 95 % CI 1.01–2.36, p = 0.04). From comparative groups, patients with primary aldosteronism had a lower level of insulin sensitivity indicators in comparison with normal group (p < 0.01). On the other hand, insulin resistance which presented by HOMA index was stronger in PA group than in normal control group (WMD = 0.41, 95 % CI 0.17, 0.65; p = 0.001), whereas it was weaker than that in EH group (WMD = −0.37, 95 % CI −0.62, −0.13; p = 0.003).

Conclusion

There is a significant prevalence of elevated level of glucose metabolism in patients with PA. Awareness and treatment of this pre-diabetic or diabetic state are necessary.

Nur mit Berechtigung zugänglich

Conn JW (1965) Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med 273(21):1135–1143PubMedCrossRef

Fallo F, Veglio F, Bertello C et al (2006) Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 91(2):454–459PubMedCrossRef

Connell JM, MacKenzie SM, Freel EM et al (2008) A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev 29(2):133–154PubMedCrossRef

Quinkler M, Born-Frontsberg E, Fourkiotis VG (2010) Comorbidities in primary aldosteronism. Horm Metab Res 42(6):429–434PubMedCrossRef

Strauch B, Widimsky J, Sindelka G et al (2003) Does the treatment of primary hyperaldosteronism influence glucose tolerance? Physiol Res 52(4):503–506PubMed

Colussi G, Catena C, Lapenna R et al (2007) Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 30(9):2349–2354PubMedCrossRef

Giacchetti G, Ronconi V, Turchi F et al (2007) Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens 25(1):177–186PubMedCrossRef

Kreze AS, Kreze-Spirova E, Mikulecky M (2000) Diabetes mellitus in primary aldosteronism. Bratisl Lek Listy 101(4):187–190PubMed

Choi CS, Thompson CB, Leong PK et al (2001) Short-term K(+) deprivation provokes insulin resistance of cellular K(+) uptake revealed with the K(+) clamp. Am J Physiol Renal Physiol 280(1):F95–F102PubMed

10.

Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283(15):2008–2012PubMedCrossRef

11.

Singer S, Das-Munshi J, Brahler E (2010) Prevalence of mental health conditions in cancer patients in acute care–a meta-analysis. Ann Oncol 21(5):925–930PubMedCrossRef

12.

Biddle DA, Morris SB (2011) Using Lancaster’s mid-P correction to the Fisher’s exact test for adverse impact analyses. J Appl Psychol 96(5):956–965PubMedCrossRef

13.

Lydersen S, Laake P (2003) Power comparison of two-sided exact tests for association in 2 × 2 contingency tables using standard, mid p and randomized test versions. Stat Med 22(24):3859–3871PubMedCrossRef

14.

Brown L, Cai T, DasGupta A (2001) Interval estimation for a binomial proportion. Stat Sci 16:101–117

15.

Higgins JP, Green S, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, in http://www.cochrane-handbook.org/

16.

Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634PubMedCentralPubMedCrossRef

17.

Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101PubMedCrossRef

18.

Catena C, Lapenna R, Baroselli S et al (2006) Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 91(9):3457–3463PubMedCrossRef

19.

Fallo F, Della Mea P, Sonino N et al (2007) Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens 20(8):855–861PubMedCrossRef

20.

Haluzik M, Sindelka G, Widimsky J Jr et al (2002) Serum leptin levels in patients with primary hyperaldosteronism before and after treatment: relationships to insulin sensitivity. J Hum Hypertens 16(1):41–45PubMedCrossRef

21.

Iacobellis G, Petramala L, Cotesta D et al (2010) Adipokines and cardiometabolic profile in primary hyperaldosteronism. J Clin Endocrinol Metab 95(5):2391–2398PubMedCrossRef

22.

Ishimori M, Takeda N, Okumura S et al (1994) Increased insulin sensitivity in patients with aldosterone producing adenoma. Clin Endocrinol (Oxf) 41(4):433–438CrossRef

23.

Matrozova J, Steichen O, Amar L et al (2009) Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension 53(4):605–610PubMedCrossRef

24.

Mosso LM, Carvajal CA, Maiz A et al (2007) A possible association between primary aldosteronism and a lower beta-cell function. J Hypertens 25(10):2125–2130PubMedCrossRef

25.

Reincke M, Meisinger C, Holle R et al (2010) Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn’s Registry. Horm Metab Res 42(6):435–439PubMedCrossRef

26.

Widimsky J Jr, Sindelka G, Haas T et al (2000) Impaired insulin action in primary hyperaldosteronism. Physiol Res 49(2):241–244PubMed

27.

Widimsky J Jr, Strauch B, Sindelka G et al (2001) Can primary hyperaldosteronism be considered as a specific form of diabetes mellitus? Physiol Res 50(6):603–607PubMed

28.

Sindelka G, Widimsky J, Haas T et al (2000) Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment. Exp Clin Endocrinol Diabet 108(1):21–25

29.

Fischer E, Adolf C, Pallauf A et al. (2013) Aldosterone excess impairs first phase insulin secretion in primary aldosteronism. J Clin Endocrin Metab 98(6):2513–2520

30.

Nanba K, Tamanaha T, Nakao K et al (2012) Confirmatory testing in primary aldosteronism. J Clin Endocrinol Metab 97(5):1688–1694PubMedCrossRef

31.

Reungjui S, Pratipanawatr T, Johnson RJ et al (2008) Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia. Curr Opin Nephrol Hypertens 17(5):470–476PubMedCentralPubMedCrossRef

32.

Yokoshiki H, Sunagawa M, Seki T et al (1998) ATP-sensitive K + channels in pancreatic, cardiac, and vascular smooth muscle cells. Am J Physiol 274(1 Pt 1):C25–C37PubMed

33.

Fallo F, Pilon C, Urbanet R (2012) Primary aldosteronism and metabolic syndrome. Horm Metab Res 44(3):208–214PubMedCrossRef

34.

Underwood PC, Adler GK (2013) The renin angiotensin aldosterone system and insulin resistance in humans. Curr Hypertens Rep 15(1):59–70PubMedCentralPubMedCrossRef

35.

Vaidya A, Underwood PC, Hopkins PN et al (2013) Abnormal aldosterone physiology and cardiometabolic risk factors. Hypertension 61(4):886–893PubMedCentralPubMedCrossRef

Titel: Elevated prevalence of abnormal glucose metabolism in patients with primary aldosteronism: a meta-analysis
verfasst von: W. Chen
F. Li
C. He
Y. Zhu
W. Tan
Publikationsdatum: 01.06.2014
Verlag: Springer London
Erschienen in: Irish Journal of Medical Science (1971 -) / Ausgabe 2/2014
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-013-1007-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Elevated prevalence of abnormal glucose metabolism in patients with primary aldosteronism: a meta-analysis

Abstract

Objective

Method

Result

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Objective

Method

Result

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Modest correlation between serum neopterin levels and Gensini scores in a cohort of patients undergoing coronary angiography

A case of renal γ2 heavy-chain deposition disease accompanied by rapid progressive renal failure

Prescribing of antidiabetic therapies in Ireland: 10-year trends 2003–2012

Mid-term follow-up of stenting in chronic mesenteric ischaemia: a review of six cases

Alcohol consumption in pregnancy: results from the general practice setting

Tinzaparin safety and efficacy in pregnancy

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin